Thedja Meta Dewi, Ie Susan Irawati, Harahap Alida Roswita, El-Khobar Korri Elvanita, Roni Martono, Muljono David Handojo
Eijkman Institute for Molecular Biology, Jl. Diponegoro 69, Jakarta, 10430, Indonesia.
Eijkman Winkler Institute, Utrecht Medical Centre, Utrecht, The Netherlands.
Hepatol Int. 2013 Oct;7(4):969-80. doi: 10.1007/s12072-013-9438-z. Epub 2013 May 23.
Chronic hepatitis B (CHB) is a state of complex interactions between the hepatitis B virus (HBV) and host. We studied the changes in hepatitis B surface antigen (HBsAg), hepatitis B 'e' antigen (HBeAg) and HBV DNA levels, considering the implications of HBV genotype, basal core promoter (BCP) A1762T/G1764A and precore G1896A mutations in CHB.
One hundred fifty-two treatment-naïve CHB patients were classified into immune-tolerant (IT), immune-clearance (IC), low/non-replicative (LR) and 'e'-negative hepatitis B (ENH) phases, based on HBeAg status, HBV DNA and ALT levels. HBV DNA was detected and quantified by polymerase chain reaction, then analyzed by sequencing. HBsAg and HBeAg levels were measured serologically.
HBsAg and HBV DNA levels varied between CHB phases, with HBsAg highest in IT and lowest in LR, and HBV DNA high in IT and IC, and lowest in LR. Both markers increased in ENH. Correlation between HBsAg and HBV DNA was significant in IT and IC, modest in ENH, but missing in LR. HBeAg and HBV DNA levels were dissociated in HBeAg-positive patients. Genotypes B and C were similarly distributed, with precore mutations higher in HBeAg-negative patients and BCP mutations comparable in all phases. Temporal association between HBeAg seroconversion and an increase of BCP/precore mutations was observed.
HBsAg and HBV DNA levels were high and correlated in early CHB phases and dissociated after HBeAg seroconversion, indicating different controls affecting HBV replication and HBsAg production. Selection of BCP/precore mutants may affect disease course and explain the HBeAg-HBV DNA dissociation, a precaution for clinical application of quantitative HBeAg.
慢性乙型肝炎(CHB)是乙肝病毒(HBV)与宿主之间复杂相互作用的一种状态。我们研究了乙肝表面抗原(HBsAg)、乙肝e抗原(HBeAg)和HBV DNA水平的变化,同时考虑了HBV基因型、基本核心启动子(BCP)A1762T/G1764A和前核心区G1896A突变在CHB中的影响。
152例未经治疗的CHB患者根据HBeAg状态、HBV DNA和ALT水平分为免疫耐受(IT)、免疫清除(IC)、低/非复制(LR)和e抗原阴性乙肝(ENH)期。通过聚合酶链反应检测并定量HBV DNA,然后进行测序分析。采用血清学方法检测HBsAg和HBeAg水平。
CHB各期的HBsAg和HBV DNA水平有所不同,HBsAg在IT期最高,LR期最低,HBV DNA在IT期和IC期较高,LR期最低。这两种标志物在ENH期均升高。HBsAg与HBV DNA在IT期和IC期显著相关,在ENH期相关性中等,但在LR期无相关性。在HBeAg阳性患者中,HBeAg与HBV DNA水平分离。B型和C型基因型分布相似,前核心区突变在HBeAg阴性患者中较高,BCP突变在各期相当。观察到HBeAg血清学转换与BCP/前核心区突变增加之间的时间关联。
在CHB早期,HBsAg和HBV DNA水平较高且相关,HBeAg血清学转换后两者分离,表明影响HBV复制和HBsAg产生的调控机制不同。BCP/前核心区突变体的选择可能影响疾病进程,并解释HBeAg-HBV DNA分离现象,这是定量HBeAg临床应用时需要注意的问题。